SEC Form 4 · accession 0001144204-16-127046
CASI Pharmaceuticals, Inc. · CASI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ken Keyong Ren
Officer — Chief Executive Officer · Director
Period of report
Oct 3, 2016
Accepted (ET)
Oct 5, 2016 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000895051
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy) | $1.11 | Oct 3, 2016 | A | 308,571 | A | Oct 3, 2016 | Oct 3, 2026 | Common Stock | 308,571 | 308,571 | D |